DOCSLIB.ORG

Toxicologic Pathology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toxicologic Pathology Toxicologic Pathology http://tpx.sagepub.com/ Renal Papillary Necrosis−−40 Years On Peter H. Bach and Nguyen Thi Kim Thanh Toxicol Pathol 1998 26: 73 DOI: 10.1177/019262339802600110 The online version of this article can be found at: http://tpx.sagepub.com/content/26/1/73 Published by: http://www.sagepublications.com On behalf of: Society of Toxicologic Pathology Additional services and information for Toxicologic Pathology can be found at: Email Alerts: http://tpx.sagepub.com/cgi/alerts Subscriptions: http://tpx.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav Citations: http://tpx.sagepub.com/content/26/1/73.refs.html >> Version of Record - Jan 1, 1998 What is This? Downloaded from tpx.sagepub.com by guest on December 5, 2011 TOXICOLOGICPATHOLOGY, vol. 26, no. 1, pp. 73-91, 1998 Copyright 0 1998 by the Society of Toxicologic Pathologists Renal Papillary Necrosis40 Years On* F'EER H. BACHAND NGUYENTHI KIM THANH BioMedical Research Centre, Division of Biomedical Sciences, Slieffield Hallam University, Shefield SI I WB, England, United Kitigdoiii ' ABSTRACT Analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) are well recognized as a major class of therapeutic agent that causes renal papillary necrosis (RPN). Over the last decade a broad spectrum of other therapeutic agents and many chemicals have also been rcportcd that have the potential to cause this lesion in animals and man. There is consensus that RPN is the primary lesion that can progress to cortical degeneration; and it is only at this stage that the lesion is easily diagnoscd. In the absence of sensitive and selective noninvasive biomarkers of RPN there is still no clear indication of which compound, under what circumstances, has the greatest potential to cause this lesion in man. Attempts to mimic RPN in rodents using analgesics and NSAIDs have not provided robust models of the lesion. Thus, much of the research has concentrated on those compounds that cause an acute or subacute RPN as the basis by which to study the pathogenesis of the lesion. Based on the mechanistic understanding gleaned from these model compounds it has been possible to transpose an understanding of the underlying processes to the analgesics and NSAIDs. The mechanism of RPN is still controversial. There are data that support microvascular changes and local ischemic injury as the underlying cause. Alternatively, several model papillotoxins, some analgesics, and NSAIDs target selectively for the medullary interstitial cells, which is the earliest reported aberration, after which there are a series of degenerative processes affecting other renal cell types. Many papillotoxins have the potential to undergo prostaglandin hydroperoxidase-mediated metabolic activation, specifically in the renal medullary interstitial cells. These reactive intermediates, in the presence of large quantities of polyunsaturated lipid droplets, result in localized and selective injury of the medullary interstitial cells. These highly differentiated cells do not repair, and it is generally accepted that continuing insult to these cells will result in their progressive erosion. The loss of these cells is thought to be central to the degenerative cascade that affects the cortex. There is still a need to understand better the primary mechanism and the secondary consequences of RPN so that the risk of chemical agents in use and novel molecules can be fully assessed. Kepr*ords. Analgesic ncphropathy; renal papillary necrosis; nonsteroidal anti-inflammatory drugs INTRODUCHON condition tends to be low and does not adequately reflect Renal papillary necrosis (RF") was first described as a the regional levels of renal disease that may occur. RPN common condition in human diabetic patients, but there in humans develops as a result of chronic consumption or was a progressive realization that RPN has other causes long-term abuse of single and mixed analgesics. The lesion (13), especially as a consequence of analgesic abuse, as also occurs in adults and children who have been pre- many thousands of patients took excessive quantities of scribed NSAIDs, and single analgesics, and it has also mixed analgesics in the 1960-1980s. Initially phenacetin been implicated with a whole spectrum (Table I) of ther- was assumed to be the nephrotoxic common denominator apeutically used NSAIDs and some other drugs. (50, 51, 150, 151), and this compound was progressively banned from over-the-counter (OTC) products, but it is ANALGESICNEPHROPATHY now appreciated that many analgesics and nonsteroidal The progression of renal failure in analgesic-associated anti-inflammatory drugs (NSAIDs) have papillotoxic po- nephropathy has been well documented (13, 32, 47, 78, tential if used in excessive quantities. It is also apparent 96, 142, 170, 171, 203, 204). Analgesic nephropathy is that the problem of excessive use of analgesics continues a degenerative condition leading to renal failure follow- today (13, 46, 56, 87, 96, 171, 185, 200, 201) and this ing long-term analgesic abuse. Pyelonephritis is a hall- healthcare cost is probably preventable (46, 47, 59). An- mark, as a result of an RPN. There are few clinical symp- algesic abuse is a frequent cause of analgesic nephropathy toms associated with the early development of analgesic- that leads to end-stage renal disease and upper urothelial associated RF" (13, 32, 78, 171, 203, 204). The pro- carcinoma throughout Europe (46, 47, 58-64, 179, 180, gression of renal damage is insidious and renal function 203, 204), Australia (149-150, 171, 216), and other parts may be severely compromised before the condition be- of the world (206-210). Interestingly, there are apparently comes obvious (13, 32, 78, 171, 203, 204). only few cases in the USA (21, 29, 56, 96, 184, 200, 201, 226). The condition occurs in national or local clusters, Early symptoms include headaches, upper gastrointes- for reasons that are not clear, but may relate to social cus- tinal disease such as peptic ulceration of stomach and toms, availability of specific medications, or other as yet duodenum, dyspepsia and anemia as a result of gastro- poorly identified factors. Thus, national incidence for the intestinal tract bleeding, hemolysis, and iron deficiency. These are often seen in patients who have emotional * Address all correspondence to: Dr. Peter H. Bach, BioMedical Re- dependence, anxiety, introversion, and neurosis. search Centre, Division of Biomedical Sciences, Sheffield Hallam Uni- Intermediate symptoms include urinary tract disease versity, Pond Street, Sheffield S1 IWB, England, United Kingdom. such as nocturia, dysuria, bacteriuria, sterile pyuria, 73 0192-6233/98$3.00+$0.00 Downloaded from tpx.sagepub.com by guest on December 5, 2011 74 BACHANDTHANH TOXICOLOGICPATHOLOGY TABLEI.-Chemicals and therapeutic agents reprted to cause papillary 3) The late symptoms such as hypertension, cardiovas- necrosis in animals or linked to case reports of papillary necrosis in man. cular disease, peripheral vascular disease, renal calculi and bladder stones and decreased glomerular filtration Chemical or rherapeutic agent References rate, increased blood urea nitrogen, renal tubular aci- Acetaminophen 210 Antipyrine 111 dosis, and carcinoma of upper renal tract are common, Aspirin 30,31,39,4-2, 113 but all these conditions could also have other causes. Benoxaprofen 2 Even radiological examination may not identify pap- 2,2-Bis(bromomethyl)- .3-propanediol I 65 iti 2-Bromoethanamine 13 illary necrosis (if the necrosed papillae remains 3-Bromopropanamine I83 situ), and even when loss of the papillae is obvious Butylated hydroxyanisole 93 (in the presence or absence of other degenerative renal Cacodylic acid 165 2-Chloro-N,N-dimethylethanamine 183 changes) the underlying cause still has to be estab- 2-Chloroethanamine 183 lished. Recently, the combined use of computerized 1 -(2-Chloroethyl)-3-(trans-4- 127 methylcyclohexy1)- 1-nitrosourea tomography and ultrasound ensured a very high de- Cyclophosphamide 175 gree of positive diagnosis (28, 58, 63). The use of Dapsone 37 these diagnostic criteria has resulted in the increased Dibromoneopentyl glycol 65 Diclofenac sodium 205 incidence of previously undiagnosed RPN and anal- Dimethanesulfonate 176 gesic nephropathy (64) in populations where pyelo- Dimethylarsinic acid 165 nephritis had previously been recognized but the un- Diphenylaminc 135-137 Ethoxyquin 91, 146, 147 derlying cause not identified. Ethyleneirnine 13 Fenoprofen 109 Analgesic nephropathy is also reported in patients who Flurbiprofen 167 have taken no phenacetin but who have abused acetyl- Formaldehyde 222 Ibuprofen 212 salicylic acid, acetaminophen, and codeine (60, 174), and Indometacin 2 sales figures of analgesics are presented that suggest sim- Indomethacin 33. 153 Ipsapirone 188 ilarities between the occurrence of the disease and the Ketoprofen 2 sale of the most often consumed coformulated products hlefenamic acid 33.36.98.209 (60, 174). These are thought to warrant legislative mea- hiesalazine 22, 169,221 surements to control analgesic consumption (62). These hiixed analgesics 47.50-52.61, 149-151, data are supported by the changing incidence of analgesic 170-172, 179, 180, 184 nephropathy in Australia where phenacetin was with- I-Naphthol 181 Naproxen 2.35 drawn and the potential to abuse coformulated mixed an- Nefiracetam 117,218 algesics was limited (216). The data are controversial o-Ormaplatin 126 Pentazocine and aspirin I62 from
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Extraction and Evaporation: Experiment 1 Separating the Components of a Mixture1 Week 1
    Organic Chemistry I Laboratory Extraction and Evaporation: Experiment 1 Separating the Components of a Mixture1 Week 1 Background Reading Zubrick, J. W. The Organic Chem Lab Survival Manual, 4th edition, Wiley & Sons, Inc., New York, 1997. Keeping a Notebook: Pg 12-24. Interpreting Handbooks: Pg 26-31, 34-44. Extraction and Washing: Pg 148-168. Background Senario One of the many places organic chemists are employed is in private laboratories associated with consulting firms. The purpose of these labs is generally to provide chemical analysis or synthesis of material for customers. The first few labs in CHM 220 will teach you the basic techniques needed to analyze and purify mixtures to determine the individual components. This first lab will involve determining the composition of a possible pharmaceutical preparation. Watchdog agencies exist which monitor the pharmaceuticals sold over the counter in the United States. These agencies will use private laboratory firms to analyze products suspected of violating enforced standards. For example, a new brand of analgesic may appear on drugstore shelves at a low price. The label indicates that the tablets were manufactured in the United States by a legitimate pharmaceutical company. However, the labels may reveal discrepancies and the appearance/quality of the tablets could lead an investigator to suspect that they might be counterfeit. Such knockoffs of a domestic product can be manufactured cheaply elsewhere and smuggled into the US, where they are sold for high profits. This laboratory exercise places you in the position of analyzing a suspected counterfeit analgesic preparation. The label on the suspected bottle lists the ingredients per tablet as aspirin (200 mg), acetaminophen (250 mg), and sucrose (50 mg).
    [Show full text]
  • Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic Response Identical to That Obtained by Complex Environment Rearing
    Neuropsychopharmacology (2006) 31, 90–100 & 2006 Nature Publishing Group All rights reserved 0893-133X/06 $30.00 www.neuropsychopharmacology.org Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic Response Identical to that Obtained by Complex Environment Rearing ,1 1 1 1 Keith J Murphy* , Andrew G Foley , Alan W O’Connell and Ciaran M Regan 1 Department of Pharmacology, Applied Neurotherapeutics Research Group, Conway Institute, University College Dublin, Belfield, Dublin, Ireland Recent data suggest that Alzheimer’s patients who discontinue treatment with cholinesterase inhibitors have a significantly delayed cognitive decline as compared to patients receiving placebo. Such observations suggest cholinesterase inhibitors to provide a disease- modifying effect as well as symptomatic relief and, moreover, that this benefit remains after drug withdrawal. Consistent with this suggestion, we now demonstrate that chronic administration of tacrine, nefiracetam, and deprenyl, drugs that augment cholinergic function, increases the basal frequency of dentate polysialylated neurons in a manner similar to the enhanced neuroplasticity achieved through complex environment rearing. While both drug-treated and complex environment reared animals continue to exhibit memory- associated activation of hippocampal polysialylated neurons, the magnitude is significantly reduced suggesting that such interventions induce a more robust memory pathway that can acquire and consolidate new information more efficiently. This hypothesis is
    [Show full text]
  • Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19
    Supplemental Information Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi1,2,¶, Koichi Watashi1,2,3,4*, Wakana Saso1,5.6,¶, Kaho Shionoya1,2, Shoya Iwanami7, Takatsugu Hirokawa8,9,10, Tsuyoshi Shirai11, Shigehiko Kanaya12, Yusuke Ito7, Kwang Su Kim7, Kazane Nishioka1,2, Shuji Ando13, Keisuke Ejima14, Yoshiki Koizumi15, Tomohiro Tanaka16, Shin Aoki16,17, Kouji Kuramochi2, Tadaki Suzuki18, Katsumi Maenaka19, Tetsuro Matano5,6, Masamichi Muramatsu1, Masayuki Saijo13, Kazuyuki Aihara20, Shingo Iwami4,7,21,22,23, Makoto Takeda24, Jane A. McKeating25, Takaji Wakita1 1Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 2Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, 3Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan, 4MIRAI, JST, Saitama 332-0012, Japan, 5The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, 6AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 7Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, 8Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan, 9Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan, 10Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan, 11Faculty of Bioscience, Nagahama Institute
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System S
    Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three- Dimensional Human Liver Microphysiological System The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Tsamandouras, N., T. Kostrzewski, C. L. Stokes, L. G. Griffith, D. J. Hughes, and M. Cirit. “Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three- Dimensional Human Liver Microphysiological System.” Journal of Pharmacology and Experimental Therapeutics 360, no. 1 (October 19, 2016): 95–105. As Published http://dx.doi.org/10.1124/JPET.116.237495 Publisher American Society for Pharmacology & Experimental Therapeutics (ASPET) Version Final published version Citable link http://hdl.handle.net/1721.1/117617 Terms of Use Creative Commons Attribution-NonCommercial 4.0 International Detailed Terms http://creativecommons.org/licenses/by-nc/4.0/ Downloaded from jpet.aspetjournals.org at ASPET Journals on August 30, 2018 95 105, January 2017 – and the associ- ” http://dx.doi.org/10.1124/jpet.116.237495 c clearance, as assessed in vitro, g metabolism in the context of a J Pharmacol Exp Ther 360:95 average individual, “ Several in vitro systems have been traditionally applied to ated interindividual variability is not obtained. variability in intrinsic metaboli needstobecoupledwiththepopulationvariabilityassociated with other physiologic processes indrug vivo binding (e.g., to hepatic plasma bloodpredictions proteins, flow, etc.). at Thus, to theapproach perform population (Trame in vivo et level,results al., a are 2016) integrated systems is into pharmacology desirable,pharmacokinetic population physiologically (PBPK) where based models the (Rostami-Hodjegan, inJones and 2012; vitro Rowland-Yeo, 2013; Tsamandouras et al., 2015a,b).
    [Show full text]
  • Cognitive Enhancers
    Cognitive enhancers Memory enhancers are often referred to as "smart drugs", "study drugs",[1] "smart nutrients", "cognitive enhancers", "brain enhancers" or in the scientific literature as nootropics.[2] They are drugs that are purported to improve human cognitive abilities.[3][4] The term covers a broad range of substances including drugs, nutrients and herbs with purported cognitive enhancing effects. The word nootropic was coined in 1964 by Dr. Corneliu E. Giurgea, derived from the Greek words noos, or "mind," and tropein meaning "to bend/turn". Typically, nootropics are thought to work by altering the availability of the brain's supply of neurochemicals (neurotransmitters, enzymes, and hormones), by improving the brain's oxygen supply, or by stimulating nerve growth. However the efficacy of nootropic substances in most cases has not been conclusively determined. This is complicated by the difficulty of defining and quantifying cognition and intelligence. Contents 1 Availability 2 Examples 2.1 Stimulants 2.2 Replenishing and increasing neurotransmitters 2.2.1 Cholinergics 2.2.1.1 Piracetam 2.2.1.2 Aniracetam 2.2.1.3 Other cholinergics 2.2.1.4 Acetylcholinesterase inhibitors 2.2.2 Dopaminergics 2.2.3 Serotonergics 2.3 Anti-depression, adaptogenic (antistress), and mood stabilization 2.4 Brain function and improved oxygen supply 2.5 Purported memory enhancement and learning improvement 2.6 Nerve growth stimulation and brain cell protection 2.7 Recreational drugs with purported nootropic effects 2.8 Dietary nootropics 2.9 Other nootropics 2.9.1 Contentious or possibly unsafe nootropics 3 See also 3.1 Brain and neurology 3.2 Thought and thinking (what nootropics are used for) 3.3 Health 4 References 5 External links Availability Currently there are several drugs on the market that improve memory, concentration, planning and reduce impulsive behavior.
    [Show full text]
  • World of Cognitive Enhancers
    ORIGINAL RESEARCH published: 11 September 2020 doi: 10.3389/fpsyt.2020.546796 The Psychonauts’ World of Cognitive Enhancers Flavia Napoletano 1,2, Fabrizio Schifano 2*, John Martin Corkery 2, Amira Guirguis 2,3, Davide Arillotta 2,4, Caroline Zangani 2,5 and Alessandro Vento 6,7,8 1 Department of Mental Health, Homerton University Hospital, East London Foundation Trust, London, United Kingdom, 2 Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 4 Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, 5 Department of Health Sciences, University of Milan, Milan, Italy, 6 Department of Mental Health, Addictions’ Observatory (ODDPSS), Rome, Italy, 7 Department of Mental Health, Guglielmo Marconi” University, Rome, Italy, 8 Department of Mental Health, ASL Roma 2, Rome, Italy Background: There is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders. While treating cognitive deficit symptoms in neuropsychiatric or neurodegenerative disorders using CEs might have significant benefits for patients, the increasing recreational use of these substances by healthy individuals raises many clinical, medico-legal, and ethical issues. Moreover, it has become very challenging for clinicians to Edited by: keep up-to-date with CEs currently available as comprehensive official lists do not exist. Simona Pichini, Methods: Using a web crawler (NPSfinder®), the present study aimed at assessing National Institute of Health (ISS), Italy Reviewed by: psychonaut fora/platforms to better understand the online situation regarding CEs.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Metabolism of Phenacetin in the Rat
    METABOLISM OF PHENACETIN IN THE RAT CONRAD AGNELLO D'SOUZA B.Pharm. submitted in partial fulfilment of the requirements for the degree of Master of Pharmacy UNIVERSITY OF TASMANIA HOBART SEPTEMBER 1983. ‘, r \ytTL- cua biA-- 11\esi5 ekci tr vv. t1, PJiar,c\ b'Souz4 THE UNIVERSITY Of TASMANIA' LIBRARY 11L4 VI I SUMMARY The abuse of phenacetin-containing analgesic mixtures has been linked epidemiologically with nephrotoxicity and carcinogenicity in man. In addition, clinical and histopathological tests after chronic administration of phenacetin in man and animals have indicated that it is nephrotoxic and carcinogenic. Furthermore, it has a chemical similarity to other known carcinogenic arylamides. However, the induction of toxicity with phenacetin remains a controversial subject. A number of chronic dosing studies with phenacetin have been carried out to demonstrate the ability of the drug to induce carcinogenesis and nephropathy. However, none have sought to explain the reasons for the chronic nature of phenacetin toxicity on the basis of the increased formation of toxic metabolites after continued administration of the drug. In the present chronic daily-dosing study with phenacetin in the rat, the metabolism of the drug was monitored by analysing urine samples at regular weekly intervals. Particular attention was paid to the formation of N-hydroxyphenacetin, which has been implicated in phenacetin carcinogenicity. The metabolism of phenacetin was monitored in five groups of Hooded Wistar rats. Each group was subjected to a different treatment. The purpose was to elucidate the effects of the size of the dose, duration of treatment, influence of commonly co- administered drugs (aspirin, caffeine) and the influence of a sulfation inhibitor (pentachlorophenol) on the metabolism of phenace tin.
    [Show full text]